Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma
Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.
Previous Post
Diagnostic Imaging's Weekly Scan: August 11 — August 17 (Video Version)
Next Post
Navigating Challenges in Pediatric Dermatology Access, Addressing Disparities: Elizabeth Garcia Creighton
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago